2023 Fiscal Year Final Research Report

Relation between physical/psychiatric symptoms of irritable bowel syndrome and gluten sensitivity

Research Project

PDF

Project/Area Number	21K07381
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Review Section	Basic Section 52010:General internal medicine-related
Research Institution	Hyogo Medical University
Principal Investigator	Maebayashi Kensei 兵庫医科大学, 医学部, 助教 (10595317)
Co-Investigator(Kenkyū-buntansha)	吉村知穂兵庫医科大学, 医学部, 助教 (10648166) 山田恒兵庫医科大学, 医学部, 講師 (20464646) 本山美久仁兵庫医科大学, 医学部, 博士研究員 (20873615)
Project Period (FY)	2021-04-01 – 2024-03-31
Keywords	グルテン不耐症 / グルテン感受性 / 過敏性腸症候群 / グルテンフリー食 / 抗グリアジンIgG抗体
Outline of Final Research Achievements	We investigated the association between irritable bowel syndrome (IBS) and gluten intolerance. Anti-gliadin IgG antibodies were measured in blood of patients with gluten intolerance and healthy subjects. We assessed IBS, physical/psychiatric symptoms, and quality of life. Approximately 60% of patients with gluten intolerance met the diagnostic criteria for IBS, and approximately 40% of gluten intolerant and 40% of IBS patients were positive for anti-gliadin IgG antibodies. There is an overlap between IBS and gluten intolerance, and it seems that patients with gluten intolerance are included among IBS patients. Anti-gliadin IgG antibodies may be useful as a marker for patients with IBS whose symptoms improve with gluten restriction.
Free Research Field	精神医学
Academic Significance and Societal Importance of the Research Achievements	本研究では、IBSとグルテン不耐症はオーバーラップしており、IBS患者にグルテン不耐症患者が含まれている可能性が示唆され、グルテン制限やグルテンフリーで症状が改善するIBS患者のマーカーとして、抗グリアジンIgG抗体が有用な可能性があることが分かった。今後、抗グリアジンIgG抗体陽性のIBSに対するグルテンフリー食の治療有効性を検証し、有効性が認められれば、治療選択の最適化が可能になると想定される。グルテンフリー食という介入方法は、安全性に優れ、臨床応用も容易であり、有益なものとなることが期待される。